India’s first Cas9 protein based CRISPR Covid-19 test FELUDA approved for use
India’s first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) based COVID-19 test called FELUDA has been approved for use. FELUDA is jointly developed by CSIR-Institute of Genomics & Integrative Biology (IGIB) and TATA Medical and Diagnostics Ltd. FELUDA has 96% sensitivity and 98% specificity for detecting SARSCoV2. CRISPR is a genome-editing technology to diagnosing diseases.
As per the developers, the Tata CRISPR test achieves accuracy levels of RT-PCR tests with quicker turnaround time. So far, FELUDA is the only test which uses Cas9 protein for detection. This test is also cheaper than the available tests in the market but the makers have not divulged the cost yet.
“This marks a significant achievement for the Indian scientific community, moving from R&D to a high-accuracy, scalable and reliable test in less than 100 days,” said a statement by the TATA Group.
Dr Anurag Agrawal, Director CSIR-IGIB said that the work started by CSIR under the sickle cell mission for genome diagnostics and therapeutics helped to fasttrack the project.
The IGIB team which developed the kit was led by Dr Debojyoti Chakraborty and Dr SouvikMaiti.
India had abruptly removed the cumulative COVID case data in August 2020, leaving just active cases for the day versus cumulative recoveries and deaths,...
A new rare disease known as mucormycosis or Black Fungus is spreading across India which the doctors say is a COVID-19 triggered disease and...
A Google Trend analysis by Tulane University reveals a major panic attack issue which the researchers are terming as a “mental health tsunami” related...
Under the agreement, RDIF shall supply to Dr Reddy’s 100 million doses of the vaccine in late 2020.